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Abstract
Background: The role of coffee consumption in the risk of cardiovascular diseases has been debated for many
years. The current study aimed to summarize earlier evidence on the effects of green coffee extract (GCE)
supplementation on glycemic indices and lipid profile.
Methods: We searched available online databases for relevant clinical trials published up to October 2019. All
clinical trials investigating the effect of GCE supplementation, compared with a control group, on fasting blood
glucose (FBG), serum insulin, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density
lipoprotein (HDL) were included. Overall, 14 clinical trials with a total sample size of 766 participants were included
in the current meta-analysis.
Results: We found a significant reducing effect of GCE supplementation on FBG (weighted mean difference (WMD):
-2.35, 95% CI: − 3.78, − 0.92 mg/dL, P = 0.001) and serum insulin (WMD: -0.63, 95% CI: − 1.11, − 0.15 μU/L, P = 0.01).
With regard to lipid profile, we observed a significant reduction only in serum levels of TC following GCE
supplementation in the overall meta-analysis (WMD: -4.51, 95% CI: − 8.39, − 0.64, P = 0.02). However, subgroup
analysis showed a significant reduction in serum TG in studies enrolled both genders. Also, such a significant
reduction was seen in serum levels of LDL and HDL when the analyses confined to studies with intervention
duration of ≥8 weeks and those included female subjects. In the non-linear dose-response analyses, we found that
the effects of chlorogenic acid (CGA) dosage, the main polyphenol in GCE, on FBG, TG and HDL were in the non-
linear fashions.
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Conclusion: In conclusion, we found that GCE supplementation improved FBG and serum levels of insulin and TC.
Also, there was a significant improvement in other markers of lipid profile in some subgroups of clinical trials.
Keywords: Chlorogenic acid, Green coffee, Lipid profile, Glycemic indices
Background
Cardiovascular diseases (CVDs) are the number one
cause of death worldwide [1]. Dyslipidemia and impaired
glucose tolerance (IGT) are among the primary risk fac-
tors for the development and progression of CVDs and
type 2 diabetes [2, 3]. Reversal of these risk factors leads
to a considerable reduction in the risk of these chronic
diseases [4–7]. Although current guideline recommends
dietary regulations as the first-line therapy for dyslipid-
emia and glucose disturbance, only a modest amelior-
ation has been achieved using these methods [8].
Coffee is widely consumed in the world containing
a range of phytochemicals. Previous studies have
shown beneficial effects of coffee consumption on
several health conditions including metabolic syn-
drome, type 2 diabetes, and vascular function [9, 10].
The most commonly found phytochemicals in the
coffee are phenolic compounds, primarily chlorogenic
acid (CGA) [11]. CGA is the ester of caffeic acid with
quinic acid that belongs to the family of hydroxycin-
namic acid [12]. Anti-lipidemic and anti-diabetic
properties of CGA have been demonstrated in animal
studies [13–15]. However, findings from human clin-
ical trials are not consistent [16–29]. Green coffee ex-
tract (GCE) and its CGA showed hypolipidemic
effects on serum levels of triglyceride (TG) and total
cholesterol (TC) in patients with IGT [29] and those
with non-alcoholic fatty liver disease [26]; however,
the effects on circulating levels of high-density lipo-
protein (HDL) and low-density lipoprotein (LDL)
were inconsistent. Some studies showed a significant
increase in serum HDL following GCE intake [17,
19], while others could not find any significant results
[20, 21, 24]. Considering insulin resistance, fasting
blood glucose (FBG) or serum insulin significantly re-
duced following GCE administration in some studies
[18, 24, 29], but no significant changes were observed
in some others [23, 27].
A previous meta-analysis of randomized controlled tri-
als (RCTs) found increased levels of serum TC, LDL,
and TG following coffee intake [30]; however, to our
knowledge, there is no study summarizing available find-
ings on the effects of green coffee consumption on gly-
cemic indices and lipid profile. Therefore, we aimed to
conduct a systematic review and meta-analysis to
summarize current evidence on the effects of GCE sup-
plementation on glycemic and lipid profiles in adults.
Methods
This study was performed based on the PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses) protocol for reporting systematic re-
views and meta-analyses [31].
Search strategy
A comprehensive literature search was performed using
online databases of PubMed, Scopus, Web of Science
and Google Scholar up to October 2019. The aim of the
search was to identify clinical trials that investigated the
effects of GCE supplementation on glycemic indices and
lipid profile in adults. The following keywords were used
in the search strategy: (“Green coffee” OR “Green coffee
extract” OR “Green coffee bean extract” OR “Chloro-
genic acid” OR “Chlorogenic” OR “GCR” OR “CGA”)
AND (Triglyceride OR Triacylglycerol OR TG OR chol-
esterol OR lipoprotein OR “very low density lipoprotein”
OR VLDL OR “low density lipoprotein” OR LDL OR
“high density lipoprotein” OR HDL OR “lipid profile”
OR “fasting blood sugar” OR glucose OR insulin OR “
glycosylated hemoglobin” OR HbA1c OR FBS OR FBG).
No restriction was considered for the time and language
of publications. We conducted a manual search in the
reference lists of the relevant studies to avoid missing
any eligible publication. Unpublished studies were not
considered.
Inclusion criteria
We included eligible studies that met the following cri-
teria: 1) placebo-controlled clinical trials 2) those that
performed on adult subjects (≥18 years old), 3) studies
that administered green coffee extract in the forms of
supplement or powder added to foods or beverages, 4)
those that did intervention for at least 2 weeks, and 5)
controlled trials that reported mean changes and SDs of
glycemic indices or lipid profile throughout the trial for
both the intervention and control groups or presented
required information for calculation of those effect sizes.
If more than one article was found for one dataset, the
more complete one was selected. Clinical trials with an
additional arm were considered as 2 separate studies.
Exclusion criteria
In the current meta-analysis, we excluded:1) in vitro and
animal studies, 2) studies with a cohort, cross-sectional,
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and case-control design, 3) review articles, 3) trials with-
out a placebo or control group.
Data extraction
The following information was extracted from each eli-
gible clinical trial by two independent investigators:
name of the first author, publication year, individuals’
characteristics (mean age and sex), design, sample size
(control and intervention groups), type of intervention,
dosage of GCE and CGA, duration of intervention, and
mean changes and SDs of outcome variables throughout
the trial for the intervention and control groups. When
data for glycemic or lipid measures were reported in dif-
ferent units, we converted them to the most frequently
used unit.
Risk of bias assessment
We used the Cochrane quality assessment tool to assess
the risk of bias for each study included in the current
meta-analysis [32]. This tool contained seven domains
including random sequence generation, allocation con-
cealment, reporting bias, performance bias, detection
bias, attrition bias, and other sources of bias. Each do-
main was given a “high risk” score if RCT comprised
methodological defects that may have distorted the re-
sults, a “low risk” score if the defect was considered inef-
fectual and an “unclear risk” score if the information was
not sufficient to determine the impact. If the trial had
“low risk” for all domains, it was labeled as a high-
quality study with a totally low risk of bias. The risk of
bias assessment was done independently by two
reviewers.
Statistical analysis
Mean differences in changes of the outcome variables
(FBG, insulin, TG, TC, LDL, and HDL), comparing
GCE and control groups, were used to obtain the
overall effect sizes. When mean changes were not re-
ported, we computed them by considering changes in
each outcome variable during the intervention. If out-
come variables (FBG, TG, TC, LDL, and HDL) were
reported in mmol/L, we converted them to mg/dl
through available suitable formulas. We also con-
verted standard errors (SEs), 95% confidence intervals
(CIs), and interquartile ranges (IQRs) to SDs using
relevant formulas [33–35]. To obtain the overall effect
sizes, we applied a random-effects model taking
between-study variations into account. Heterogeneity
was determined by the I2 statistic and Cochrane’s Q
test. I2 value > 50% or P < 0.05 for the Q-test was
considered as significant between-study heterogeneity
[36, 37]. To find probable sources of heterogeneity,
subgroup analyses were performed according to the
predefined criteria including gender (both/male/
female), length of intervention (≥8/< 8 weeks), baseline
levels of glycemic and lipid measures (abnormal/nor-
mal levels) and participants’ compliance (acceptable/
non-acceptable or unclear). To determine the non-
linear potential effects of CGA dosage (mg/d) on gly-
cemic and lipid indices, fractional polynomial model-
ing was executed. Due to the lack of information on
the dosage of GCE in some included studies, we de-
cided to perform non-linear dose-response analysis
for CGA dosage. Sensitivity analysis was used to ex-
plore the extent to which inferences might depend on
a particular study. The possibility of publication bias
was evaluated by the formal test of Begg. The meta-
analysis was carried out by the use of the Stata, ver-
sion 11.2 (StataCorp). P value < 0.05 was considered
as significant level.
Results
After the initial search, a total of 1571 studies were iden-
tified. After removing duplicate publications, 976 articles
remained, out of which 958 studies were identified as
unrelated when screening for title and abstract. After
assessing the full text of remained articles, we excluded
one study in which the effects of GCE in combination
with olive leaf and beetroot were assessed [38]. We also
excluded a study by Salamat et al. [39] that reported data
only for oxidized LDL, not the natural type. Two studies
that were quasi-experimental with no control group
were excluded as well [40, 41]. Two RCTs were con-
ducted on a similar dataset; however, due to assessing
different outcome variables, both of them were included
[21, 25]. Finally, 14 studies remained for the current sys-
tematic review and meta-analysis [16–29], out of which
11 studies presented data for FBG [16, 18, 19, 22–29], 7
studies for serum concentrations of insulin [18, 19, 24–
26, 29], 13 trials for serum concentrations of TC [16–24,
26–29], and 12 trials for serum concentrations of TG,
LDL, and HDL [17–24, 26–29]. Data on other glycemic
indices including glycosylated hemoglobin A1c (HbA1c)
(n = 3) and homeostatic model assessment for insulin re-
sistance (HOMA-IR) (n = 2) were not sufficient for the
meta-analysis. Flow diagram of study selection is pre-
sented in Supplemental Figure 1.
Findings from the systematic review
Characteristics of the 14 clinical trials included in the
current systematic review are illustrated in Table 1. The
total sample size of the selected studies was 766 adult
participants including 380 subjects in the GCE group
and 386 subjects in the control group. Studies were pub-
lished from 2004 to 2019. Out of 14 included studies, 3
were performed in western countries [21, 25, 29] and
others were conducted in Asia [16–20, 22–24, 26–28].
The dosage of GCE among the included studies was
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between 90 and 6000mg/day. Also, the dosage of CGA,
as the main polyphenol in GCE, was between 13.5 and
1200 mg/day. The duration of intervention varied from 2
to 16 weeks.
Of fourteen studies, six trials administered GCE in the
form of supplement [16, 19, 23, 24, 26, 29], while eight
studies administered in the form of powder added to
boiled water or other beverages [17, 18, 20–22, 25, 27, 28].
Out of fourteen studies, two were performed on healthy
individuals [22, 27] and others were conducted on subjects
with overweight or obesity, dyslipidemia, hypertension,
metabolic syndrome, non-alcoholic fatty liver disease, im-
paired glucose tolerance and mildly xerotic skin. Accord-
ing to the Cochrane Risk of Bias Assessment tool, none of
the clinical trials had a low risk of bias in all domains of
this tool (Supplemental Table 1).
Among eleven studies on FBG, four trials reported a
lowering effect of GCE supplementation on FBG levels
[16, 24–26, 29] and the other trials revealed no significant
effect. Only in two studies, GCE supplementation could
reduce serum levels of insulin [19, 25] while the other tri-
als could not find any significant change. There were 12
clinical trials on serum concentrations of TG, from which
two studies revealed a lowering effect [26, 29], one study
showed an increasing effect [17], and the others indicated
no significant effect on serum TG concentrations follow-
ing GCE supplementation. Out of thirteen studies on TC,
3 studies found a significant reduction in serum TC con-
centrations after supplementation with GCE [19, 26, 29].
Only one study revealed a reducing effect of GCE supple-
mentation on serum concentrations of LDL [19] while
others did not reach statistical significance. Among twelve
studies on serum HDL levels, only two studies showed an
increasing effect of GCE supplementation on serum con-
centrations of HDL [17, 19] whereas others failed to find
any significant effect.
Findings from the meta-analysis
All fourteen clinical trials were included in the meta-
analysis. These studies included 766 participants aged
18 years and over. There was a trial with three interven-
tion arms with different dosages of GCE compared with
one control group [20]. This study was considered as
three separate studies. In two studies, findings were re-
ported separately for normocholesterolemic and hyper-
cholesterolemic participants [21, 25]. Therefore, we
considered each study as two separate studies.
The effect of GCE on FBG levels
Overall, 12 effect sizes from 11 clinical trials with a total
sample size of 457 participants were included in the ana-
lysis [16, 18, 19, 22–29]. After combining effect sizes, we
found a significant reducing effect of GCE supplementa-
tion on FBG levels (WMD: -2.35, 95% CI: − 3.78, − 0.92
mg/dL, P = 0.001) (Fig. 1). However, there was a moder-
ate between-study heterogeneity (I2: 46.8, P = 0.03). To
detect the sources of between-study heterogeneity, we
performed subgroup analyses according to gender (male,
female, or both), length of intervention (≥8 vs. < 8
weeks), baseline levels of FBG (≥100 vs. < 100 mg/dL)
and participants’ compliance (acceptable, non-
acceptable, or unclear) (Table 2). From these analyses,
we found that gender, baseline levels of FBG and partici-
pants’ compliance could explain between-study hetero-
geneity. In addition, GCE supplementation had a
reducing effect on FBG in studies performed on both
genders, those with an intervention duration of ≥8
weeks, and those in which participants had a good ad-
herence to the intervention. Findings from the sensitivity
analysis revealed that the overall estimate did not de-
pend on a particular study. Based on the Begg’s test and
visual inspection of funnel plot (Supplemental Figure
2A), no evidence of a publication bias was found (P =
0.21).
In the non-linear dose-response analysis, we found
that the association between dosage of CGA and FBG
levels was in a non-linear fashion (Supplemental Figure
3A); such that greater reducing effect of CGA on FBG
levels was seen at the dosage of ≥200 mg/day (Pnon-linear-
ity = 0.03).
The effect of GCE on serum concentrations of insulin
Combining 7 effect sizes from 6 studies [18, 19, 24–26,
29] that included 347 participants revealed that GCE
supplementation resulted in a significant reduction in
serum concentrations of insulin (WMD: -0.63, 95% CI:
− 1.11, − 0.15 μU/L, P = 0.01) (Fig. 2). We observed a
moderate between-study heterogeneity (I2: 49.4, P =
0.06). In the subgroup analyses, we observed that
between-study heterogeneity could be explained by gen-
der and participants’ compliance. A significant reducing
effect of GCE supplementation on serum insulin con-
centrations was also seen in all subgroups. Based on the
sensitivity analysis, no single study influenced the overall
estimate. Also, no evidence of a substantial publication
bias was found according to the Begg’s test (P = 0.45)
and funnel plot (Supplemental Figure 2B).
Based on the non-linear dose-response analysis, no
significant effect of CGA dosage on serum insulin con-
centrations was seen (Pnon-linearity = 0.62) (Supplemental
Figure 3B).
The effect of GCE on serum concentrations of TG
Totally, 12 studies with a total sample size of 642 partic-
ipants were included for this effect [17–24, 26–29].
Combining 15 effect sizes from these studies revealed no
significant effect of GCE supplementation on serum TG
concentrations (WMD: -3.17, 95% CI: − 11.82, 5.49 mg/
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dL, P = 0.47) (Fig. 3). However, between-study hetero-
geneity was significant (I2: 59.1, P = 0.002). Subgroup
analyses based on gender and length of follow-up could
decrease the between-study heterogeneity. In addition,
we found a significant lowering effect of GCE supple-
mentation on serum concentrations of TG in studies
performed on both genders. The sensitivity analysis re-
vealed that the exclusion of any particular study did not
change the overall estimate. We found no evidence of a
substantial publication bias according to the Begg’s test
(P = 0.96) and funnel plot (Supplemental Figure 2C).
In the dose-response analysis, we found a significant
non-linear association between CGA dosage and serum
TG concentrations; such that dosage of CGA from low
levels to 500mg/day had a significant lowering effect on
TG levels (Pnon-linearity = 0.01), while this beneficial effect
was reduced from dosage of 500 mg/day to higher
amounts (Supplemental Figure 4A).
The effect of GCE on serum concentrations of TC
Overall, 16 effect sizes from 13 clinical trials [16–24,
26–29] with a sample size of 662 participants were in-
cluded in the analysis. Combining these effect sizes, a
significant reduction was seen in serum concentrations
of TC following GCE supplementation (WMD: -4.51,
95% CI: − 8.39, − 0.64 mg/dL, P = 0.02) (Fig. 4). There
was an evidence of moderate between-study heterogen-
eity (I2: 44.1, P = 0.03). In the subgroup analyses, we
found that gender, length of duration, baseline levels of
TC and participants’ compliance could explain between-
study heterogeneity. Based on these analyses, the effect
of GCE supplementation on serum TC concentrations
strengthened in studies performed on females and both
genders, those with ≥8 weeks’ duration of follow-up and
studies that were performed on participants with ele-
vated baseline serum levels of TC (≥200 mg/dL). In the
sensitivity analysis, significant association attenuated
Fig. 1 Forest plot for the effect of GCE supplementation on FBG levels, expressed as mean differences between intervention and control groups.
Horizontal lines represent 95% CIs. Diamonds represent pooled estimates from random-effects analysis. GCE: green coffee extract, FBG: fasting
blood glucose, CI: confidence interval
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Table 2 Subgroup analysis on the effects of GCE supplementation on glycemic and lipid measures
Effect size, n WMD1 95% CI1 P-value2 Heterogeneity
I2 (%)3 P-heterogeneity4
The effect of GCE on FBS
Overall effect size 12 -2.35 −3.78, −0.92 0.001 45.8 0.037
Participants’ gender
Male 2 −1.32 −3.87, 1.22 0.31 0.0 0.92
Female 4 −1.13 −2.47, 0.21 0.098 57.5 0.07
Both genders 6 −3.55 −5.10, −2.01 < 0.001 36.3 0.17
Intervention duration (week)
≥ 8 11 −2.13 −3.12, −1.13 < 0.001 51.1 0.025
< 8 1 −1.40 −4.35, 1.55 0.35 – –
Baseline FBS
Elevated (≥100 mg/dL) 3 −5.28 −7.93, −2.63 < 0.001 44.10 0.17
Normal (< 100 mg/dL) 9 −1.59 −2.59, −0.58 0.002 24.20 0.23
Compliance
Acceptable 5 −3.59 −5.15, −2.04 < 0.001 47.6 0.11
Unacceptable/Unclear 7 −1.16 −2.34, 0.02 0.053 15.5 0.31
The effect of GCE on insulin levels
Overall effect size 7 −0.63 −1.11, − 0.15 0.01 49.4 0.07
Participants’ gender
Female 3 −0.31 −0.52, − 0.10 0.004 54.4 0.11
Both genders 4 −0.77 −1.21, − 0.33 0.001 26.0 0.26
Compliance
Acceptable 4 −0.77 −1.21, − 0.33 0.001 26.0 0.26
Unacceptable/Unclear 3 −0.31 −0.52, − 0.10 0.004 54.4 0.11
The effect of GCE on TG levels
Overall effect size 15 −3.17 −11.82, 5.49 0.47 59.1 0.002
Participants’ gender
Male 5 −1.05 −11.70, 9.60 0.85 0.0 0.99
Female 4 2.76 −5.18, 10.70 0.49 79.6 0.002
Both genders 6 −7.83 −15.22, −0.44 0.04 68.0 0.008
Intervention duration (week)
≥ 8 11 −2.87 −8.27, 2.53 0.29 70.6 < 0.001
< 8 4 −1.21 −11.91, 9.50 0.83 0.0 0.99
Baseline TG
Elevated (≥150 mg/dL) 4 −4.58 −12.77, 3.60 0.27 74.9 0.008
Normal (< 150 mg/dL) 11 −1.44 −7.41, 4.53 0.64 54.4 0.02
Compliance
Acceptable 8 −6.14 −12.44, 0.17 0.06 57.3 0.02
Unacceptable/Unclear 7 2.55 −4.93, 10.03 0.50 59.5 0.02
The effect of GCE on TC levels
Overall effect size 16 −4.51 −8.39, −0.64 0.02 44.1 0.03
Participants’ gender
Male 5 −1.51 −6.78, 3.75 0.57 5.6 0.38
Female 5 −5.29 −8.87, −1.71 0.004 44.2 0.13
Both genders 6 −7.48 −12.11, −2.86 0.002 60.4 0.03
Intervention duration (week)
≥ 8 12 −6.11 −8.91, −3.30 < 0.001 45.9 0.04
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after exclusion of the study by Heidari et al. [19] (WMD:
-4.11, 95% CI: − 8.61, 0.40 mg/dL, P = 0.07) and the
study by Shahmohammadi et al. [26] (WMD: -3.69, 95%
CI: − 7.47, 0.08 mg/dL, P = 0.05). However, this effect
was marginally significant. Visual inspection of funnel
plot (Supplemental Figure 2D) and findings from the
Begg’s test revealed no evidence of a substantial publica-
tion bias (P = 0.58).
Based on the dose-response analysis, no significant
non-linear association was observed between CGA
Table 2 Subgroup analysis on the effects of GCE supplementation on glycemic and lipid measures (Continued)
Effect size, n WMD1 95% CI1 P-value2 Heterogeneity
I2 (%)3 P-heterogeneity4
< 8 4 −1.22 −6.65, 4.22 0.66 26.0 0.26
Baseline TC
Elevated (≥200 mg/dL) 8 −6.06 −9.01, − 3.12 < 0.001 26.2 0.22
Normal (< 200 mg/dL) 8 −2.60 −7.28, 2.09 0.28 55.8 0.03
Compliance
Acceptable 8 −4.88 −8.53, −1.23 0.009 59.4 0.02
Unacceptable/Unclear 8 −5.26 −8.66, −1.85 0.003 27.0 0.21
The effect of GCE on LDL levels
Overall effect size 15 −2.02 −5.58, 1.54 0.27 47.6 0.02
Participants’ gender
Male 5 0.58 −4.59, 5.76 0.83 3.4 0.39
Female 4 −6.96 −10.01, −3.90 < 0.001 61.1 0.05
Both genders 6 −1.44 −5.45, 2.57 0.48 25.5 0.24
Intervention duration (week)
≥ 8 11 −5.01 −7.42, −2.61 < 0.001 47.9 0.04
< 8 4 1.70 −3.79, 7.19 0.54 0.0 0.44
Baseline LDL
Elevated (≥130 mg/dL) 2 0.10 −5.73, 5.53 0.97 28.9 0.24
Normal (< 130 mg/dL) 13 −4.63 −7.02, −2.24 < 0.001 48.3 0.03
Compliance
Acceptable 8 0.01 −3.38, 3.41 0.99 11.1 0.34
Unacceptable/Unclear 7 −6.79 −9.68, −3.90 < 0.001 39.4 0.13
The effect of GCE on HDL levels
Overall effect size 15 1.08 −0.22, 2.38 0.10 37.6 0.07
Participants’ gender
Male 5 0.06 −2.16, 2.27 0.96 0.0 0.99
Female 4 2.92 2.46, 3.39 < 0.001 62.0 0.05
Both genders 6 0.63 −1.37, 2.62 0.54 0.0 0.59
Intervention duration (week)
≥ 8 11 2.79 2.34, 3.24 < 0.001 43.0 0.06
< 8 4 0.18 −2.12, 2.49 0.88 0.0 0.99
Baseline HDL
Low (< 40 mg/dL) 5 2.87 2.41, 3.33 < 0.001 56.4 0.06
Normal (≥40 mg/dL) 10 0.34 −1.36, 2.04 0.69 0.0 0.81
Compliance
Acceptable 8 0.51 −1.06, 2.09 0.52 0.0 0.91
Unacceptable/Unclear 7 2.88 2.42, 3.14 < 0.001 48.7 0.07
1Obtained from the fixed-effects model
2Refers to the mean (95% CI)
3Inconsistency, percentage of variation across studies due to heterogeneity
4Obtained from the Q-test
Abbreviations: GCE green coffee extract, WMD weighted mean difference, CI confidence interval, TG triglycerides, TC total cholesterol, LDL low-density
lipoprotein, HDL high-density lipoprotein, FBG fasting blood glucose
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dosage and serum TC concentrations (Pnon-linearity =
0.15) (Supplemental Figure 4B).
The effect of GCE on serum concentrations of LDL
Considering 15 effect sizes from 12 studies [17–24,
26–29] which included 642 participants, no significant
effect of GCE supplementation on serum concentra-
tions of LDL was found (WMD: -2.02, 95% CI: − 5.58,
1.54 mg/dL, P = 0.26, I2: 47.6, P = 0.02) (Fig. 5). Sub-
group analyses based on gender, duration of follow-
up, baseline values of LDL, and participants’ compli-
ance could decrease between-study heterogeneity.
From these analyses, we found that GCE supplemen-
tation significantly reduced serum LDL concentrations
in studies included only female subjects, studies with
a follow-up duration of ≥8 weeks, studies that in-
cluded participants with normal baseline levels of
LDL, and those with low or unclear compliance of
participants. A sensitivity analysis revealed that the
overall effect size was not influenced by a single
study. No evidence of a substantial publication bias
was seen based on the results from the Begg’s test
(P = 0.40) and funnel plot (Supplemental Figure 2E).
In the dose-response analysis, no significant associ-
ation was found between CGA dosage and serum levels
of LDL (Pnon-linearity = 0.27) (Supplemental Figure 4C).
The effect of GCE on serum concentrations of HDL
Totally, 12 studies provided data on the effect of GCE
supplementation on serum HDL concentrations [17–24,
26–29]. Combining 15 effect sizes from these studies re-
vealed no significant effect of GCE supplementation on
HDL levels (WMD: 1.08, 95% CI: − 0.22, 2.38 mg/dL,
P = 0.10) (Fig. 6). A marginally significant between-study
heterogeneity was seen in this regard (I2: 47.6, P = 0.02).
In the subgroup analyses, we found that gender, length
of follow-up, baseline levels of HDL and participants’
compliance were potential sources of heterogeneity. In
addition, GCE supplementation resulted in a significant
increase in serum HDL concentrations in trials included
Fig. 2 Forest plot for the effect of GCE supplementation on serum insulin concentrations, expressed as mean differences between intervention
and control groups. Horizontal lines represent 95% CIs. Diamonds represent pooled estimates from random-effects analysis. GCE: green coffee
extract, WMD: weighted mean difference, CI: confidence interval
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only female subjects, studies with ≥8 weeks of interven-
tion duration, studies that were performed on partici-
pants with low levels of baseline serum HDL and studies
with low or unclear adherence of participants to inter-
vention. The sensitivity analysis revealed that the overall
estimate depended on two studies [18, 26]. When we ex-
cluded these studies, Shahmohammadi et al. (WMD:
1.32, 95% CI: 0.03, 2.62 mg/dL, P = 0.04) and Fukagawa
et al. studies (WMD: 1.44, 95% CI: 0.23, 2.64 mg/dL, P =
0.02), a significant increasing effect of GCE supplemen-
tation on serum HDL concentrations was observed. No
evidence of a substantial publication bias was seen ac-
cording to the Begg’s test (P = 0.80) and funnel plot
(Supplemental Figure 2F).
In the dose-response analysis, we found a significant
non-linear association between CGA dosage and serum
concentrations of HDL (Pnon-linearity = 0.01); such that
from dosage of 100mg/day to higher levels, CGA
administration had an increasing effect on serum HDL
concentrations (Supplemental Figure 4D).
Discussion
The role of coffee consumption in the risk of cardiovas-
cular diseases has been debated for many years. Recent
meta-analyses of prospective studies showed no potential
health risk associated with the coffee intake [42, 43] even
when heavily consumed [44]. Also, an umbrella review
of meta-analyses revealed the protective effects of coffee
consumption against cardiovascular risk factors [45].
Unlike observational studies, considerable controversy
exists among clinical trials. In the current study, we
summarized evidence from clinical trials investigating
the effect of GCE supplementation on lipid profile and
some glycemic indices. We found that GCE supplemen-
tation significantly reduced FBG and insulin levels. Con-
sidering the lipid profile, GCE supplementation resulted
Fig. 3 Forest plot for the effect of GCE supplementation on serum TG concentrations, expressed as mean differences between intervention and
control groups. Horizontal lines represent 95% CIs. Diamonds represent pooled estimates from random-effects analysis. GCE: green coffee extract,
TG: triglyceride, WMD: weighted mean difference, CI: confidence interval
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in a significant decrease in TC concentrations, but re-
sults from other lipid measures were not significant.
However, GCE supplementation improved serum levels
of TG, LDL, and HDL in some subgroups of studies.
Also, in the non-linear dose-response analyses, we found
that the associations between CGA dosage and serum
levels of FBS, TG, and HDL were in a non-linear
fashion.
We found a significant reduction in both serum levels
of FBG and insulin following GCE supplementation. In
line with our findings, Morvaridi et al. reported a benefi-
cial effect of green coffee consumption on glycemic indi-
ces and cardio-metabolic risk factors in adults [46]. In
contrast with our findings, in a meta-analysis, Kondo
et al. reported no significant effect of caffeinated/decaf-
feinated coffee consumption on FBS and insulin levels
[47]. The observed controversy in this regard might be
due to the use of different types of coffee across previous
clinical trials. Green coffee contains a higher amount of
CGA compared with other types of coffee. It seems that
the anti-diabetic effect of green coffee is attributed to its
CGA content. As seen in the dose-response analysis, the
stronger reducing effect of GCE on FBG was observed at
CGA dosage of 200 mg/d or more. CGA increases per-
ipheral glucose disposal through activating AMP-
activated protein kinase (AMPK) [48]. It also reduces
glucose production by gluconeogenesis and glycogenoly-
sis through inhibiting glucose-6-phosphatase [49]. More-
over, increased serum concentrations of adiponectin, a
protein hormone released from adipose tissue that mod-
ulates glucose regulation and fatty acid oxidation, may
play a role in the metabolic effect of CGA [50]. Reducing
blood glucose through the mentioned pathways can also
decrease insulin levels.
Fig. 4 Forest plot for the effect of GCE supplementation on serum TC concentrations, expressed as mean differences between intervention and
control groups. Horizontal lines represent 95% CIs. Diamonds represent pooled estimates from random-effects analysis. GCE: green coffee extract,
TC: total cholesterol, WMD: weighted mean difference, CI: confidence interval
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In the overall meta-analysis of the effect of GCE on
lipid profile, we found a reducing effect only on serum
levels of TC. In agreement with our findings, a prospect-
ive cohort study indicated a significant inverse associ-
ation between coffee consumption, particularly green
coffee, and TC levels [51]. Also, in an experimental
study, GCE administration could significantly reduce TC
levels [52]. In contrast, available findings on the effects
of other types of coffee on lipid profile are conflicting
[30]. Different findings might be explained by different
processing methods used for preparation of coffee. In a
systematic review, Penson et al. reported that the type of
coffee and the methods of preparation are important for
the effect of coffee consumption on serum levels of lipo-
proteins [53]. In addition, different duration of interven-
tion, recruiting participants with different health
conditions and different quality of clinical trials are other
reasons for the observed discrepancy across clinical trials
investigating the effects of coffee consumption on TC
levels.
Although the overall analysis did not show significant
effects of GCE supplementation on serum levels of LDL
and HDL, we found favorable effects in studies that re-
cruited female subjects. Further, the TC-lowering effect
increased in studies conducted on either gender or fe-
male subjects. The analysis also showed a significant re-
ducing effect of GCE on serum levels of TG and FBG
among studies that included both sexes. It seems that
sex may mediate the effect of GCE on lipid profile with
a stronger effect observed in women. It has been shown
that CGA is more durable in women than men and
therefore, had a longer effect on women than men [54].
Also, the sex differences may be mediated by changes in
steroid hormone levels [55].
In our meta-analysis, the beneficial effects of GCE sup-
plementation were mostly observed in RCTs with a long
Fig. 5 Forest plot for the effect of GCE supplementation on serum LDL concentrations, expressed as mean differences between intervention and
control groups. Horizontal lines represent 95% CIs. Diamonds represent pooled estimates from random-effects analysis. GCE: green coffee extract,
LDL: low-density lipoprotein, WMD: weighted mean difference, CI: confidence interval
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duration of the intervention (≥8 weeks). It is consistent
with the results from the previous meta-analysis on
green coffee consumption in which a longer duration (>
8 weeks) was more effective on lipid profile [56]. In a
network meta-analysis, Kondo et al. concluded that clin-
ical trials with a longer duration of intervention can bet-
ter clarify the potential effects of coffee [47]. Thus, green
coffee consumption should be long enough to improve
the lipid profile.
Dose-response analysis demonstrated a significant incre-
ment in serum levels of HDL from CGA dosage of 100
mg/day to higher amounts. Moreover, we found a signifi-
cant non-linear association between CGA dosage and
serum TG concentrations. However, the TG-lowering ef-
fect of CGA was decreased at a dosage of 500mg/d and
over. The effect of green coffee on lipid profile was also
dose-dependent in earlier meta-analyses of RCTs [56, 57].
Therefore, the dosage of CGA is a potential moderator for
the beneficial effect of GCE on lipid profile. CGA may
exert its lipid-lowering effects through inhibition of the
lipids absorption and the formation of cholesterol mi-
celles. Also, CGA is involved in modifying hepatic metab-
olism of cholesterol and fatty acids by inhibiting
pancreatic lipase and hydroxymethyl glutaryl Co-A reduc-
tase and increasing the activity of fatty acid beta-oxidation
and the expression of peroxisome proliferator-activated
receptor-alpha in the liver [13, 58]. Based on our finding,
however, higher dosages of more than 500mg/d CGA is
not recommended. Of note that higher intake of CGA
may elevate homocysteine levels, a risk factor for cardio-
vascular disease, and stimulate the release of adrenaline
generating several effects on the cardiovascular system in-
cluding increased blood pressure and reduced insulin sen-
sitivity [50, 59, 60].
Fig. 6 Forest plot for the effect of GCE supplementation on serum HDL concentrations, expressed as mean differences between intervention and
control groups. Horizontal lines represent 95% CIs. Diamonds represent pooled estimates from random-effects analysis. GCE: green coffee extract,
HDL: high-density lipoprotein, WMD: weighted mean difference, CI: confidence interval
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The current meta-analysis was the first to summarize
available findings on the effects of GCE supplementation
on glycemic and lipid profiles. The selected studies were
from different countries which increase the
generalization of findings to the various ethnic groups.
Other strengths of this meta-analysis were the inclusion
of all clinical trials written in all languages, lack of publi-
cation bias, and moderate-to-high quality of the most in-
cluded studies. However, some limitations should be
considered when interpreting our findings. These limita-
tions include the lack of evaluation of participants’ com-
pliance in a limited number of RCTs, the lack of
controlling for baseline values of glycemic and lipid
measures in some others, short duration of intervention
in some trials, and different health conditions of partici-
pants across included studies. Also, we could not find
the effect of GCE supplementation on other glycemic in-
dices such as HbA1c due to limited number of studies.
Conclusion
GCE supplementation had favorable effects on glycemic
indices including FBG and insulin levels. In terms of
lipid profile, GCE supplementation led to a significant
reduction in serum TC, particularly in individuals with
elevated levels of TC. This suggests GCE as a promising
antihyperlipidemic agent since some patients do not
achieve cholesterol reduction goals or cannot tolerate
statins due to adverse effects [61]. We also found a sig-
nificant favorable effect of GCE on serum levels of TG,
LDL, and HDL in some subgroups. The effect was more
prominent in women and studies with a long duration of
intervention. Further studies are required to find the ef-
fect of GCE supplementation on patient-reported out-
comes including quality of life, as well as the effect of
genetic polymorphisms on the pharmacokinetics of
CGA to explain the interindividual variability.
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